Explore the latest news and publications from Latigo Biotherapeutics

Pharmacologic Characterization of LTGO-33, a Selective Small Molecule Inhibitor of the Voltage-Gated Sodium Channel NaV1.8 with a Unique Mechanism of Action

February 23, 2024
Discovery and development of new molecules directed against validated pain targets is required to advance the treatment of pain disorders.
Read more

Latigo Biotherapeutics Debuts with $135 Million Series A Financing to Develop Non-Opioid Pain Medicines

February 14, 2024
Potential best-in-class lead program targets Nav1.8, a validated human target for pain.
Read more
Back To Top